RxDoctor Payments Data

Edward Stewart, DO

Cardiovascular Disease · Greenville, SCNPI 1013094234

Payments from drug & device makers

$749in general payments, 2019–2025

Across 41 payments — averaging $18.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$281
  • Johnson & Johnson$201
  • Edwards Lifesciences$111
  • Amarin Pharma, Inc.$32
  • Novartis$30
  • Atricure, Inc.$22
  • plus $72 from 4 others

What the payments were for

  • Food & beverage$749100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$749 in reported general payments places this provider in the 15th percentile of 257 cardiovascular disease providers in South Carolina.

See all cardiovascular disease providers in South Carolina

Medicare billing

Part B allowed, 2024
$555,578
Medicare patients
2,008
Services billed
6,897

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban962$997,489
Repatha SureclickEvolocumab249$251,838
XareltoRivaroxaban217$210,118
EntrestoSacubitril/Valsartan124$126,638
MultaqDronedarone Hcl44$70,843
JardianceEmpagliflozin40$43,889
Praluent PenAlirocumab34$30,285
Metoprolol Succinate886$13,885
BrilintaTicagrelor11$13,871
Flecainide Acetate215$7,944
Atorvastatin Calcium644$6,372
Losartan Potassium557$5,563
Potassium Chloride151$5,504
Ranolazine ErRanolazine44$5,209
Dabigatran EtexilateDabigatran Etexilate Mesylate15$5,172

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$281$997,489962 claims
Johnson & JohnsonXarelto$201$210,118217 claims
NovartisEntresto$30$126,638124 claims
Sanofi-aventis U.S. LLCMultaq$17$70,84344 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 257 cardiovascular disease providers in South Carolina.

Other cardiovascular disease in Greenville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →